Steven Arkin

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

Jeanne M. Lusher, Steven Arkin, Charles F. Abildgaard et al. · New England Journal of Medicine · 1993 · 493 citations · Full text

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf et al. · Blood · 2011 · 457 citations

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

Ganesh M. Shankar, Steven Arkin, Laurent Cocea et al. · The AAPS Journal · 2014 · 323 citations

Immunohematology, Peptides—harmonized Terminology, Tactical Recommendations +10

Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A

Richard S. Schwartz, Charles F. Abildgaard, Louis M. Aledort et al. · New England Journal of Medicine · 1990 · 263 citations

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A

Jeanne M. Lusher, Steven Arkin, C. F. ABILGAARD et al. · Survey of Anesthesiology · 1993 · 182 citations

Clinical Specialties, Pediatric Rehabilitation, Recombinant Factor Viii +21